ALTERITY THERAPEUTICS

Company snapshot

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. Our goal is to modify the course of these diseases and improve quality of life. Our lead asset, ATH434, has the potential to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological prot

• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 4 US patent(s) indexed to this assignee profile.
• 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for ALTERITY THERAPEUTICS. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for ALTERITY THERAPEUTICS.

1. Jun 5, 2026 Clinical update

   ATH434 dose level 1 — Phase 2

2. May 26, 2026 Clinical update

   ATH434-DP2 — Phase 2

3. May 23, 2026 Clinical update

   ATH434 — Phase 2

4. Mar 14, 2023 Patent grant

   Acyl hydrazone derivative compounds for treating disease

5. Jun 14, 2022 Patent grant

   Method of treating immunoglobulin light chain amyloidosis

View all clinical trial activity →

• What is ALTERITY THERAPEUTICS?

  Alterity Therapeutics is a pharma organization headquartered in Melbourne, AU. It trades on NYSE under ticker ATHE. Primary therapeutic focus areas include Multiple System Atrophy. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 4 patent record(s) to this entit

• Is ALTERITY THERAPEUTICS publicly traded?

  Yes. ALTERITY THERAPEUTICS is listed with ticker ATHE on NYSE per SEC EDGAR records linked on this profile.

• What drugs does ALTERITY THERAPEUTICS develop or market?

  We link 1 drug profile(s) where ALTERITY THERAPEUTICS is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/alterity-therapeutics-ltd#company-drugs.

• What are the latest developments for ALTERITY THERAPEUTICS?

  In the last 12 months our linked public records show 3 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does ALTERITY THERAPEUTICS focus on?

  ALTERITY THERAPEUTICS focuses on Multiple System Atrophy based on our analysis of their pipeline programs and drug development activities.